Novartis Successfully Completes Acquisition of AveXis, Inc.

By Cure SMA | Published On May 15, 2018

Novartis Successfully Completes Acquisition of AveXis, Inc.

Dear SMA Community, 

Following the announcement last month, we wanted to let you know that AveXis (the gene therapy company developing a new approach to treat SMA known as AVXS‐101) is officially a Novartis company.

AveXis remains steadfastly dedicated to the SMA community, and we are excited about the promise of the future as a part of this organization. As a Novartis company, we hope to accelerate our mission of bringing AVXS-101 to people with SMA as quickly and safely as possible.

If you have any questions about the acquisition or our programs in SMA, please continue to contact us at


The AveXis Team

Topics: Research, Front Page News

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software